Categories: HospitalsNewsRobotics

LEM Surgical AG Secures CHF 22 Million in Series B Funding to Ready Robotic System for FDA Submission

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BERN, SWITZERLAND / ACCESSWIRE / January 4, 2024 / LEM Surgical AG, an innovative surgical robotics company headquartered in Bern, Switzerland, announces the successful completion of its Series B funding, securing CHF 22 million. The round, which was strongly oversubscribed, reflects the strong investors’ confidence in LEM Surgical’s differentiated approach.

LEM Surgical Logo
Company Logo of LEM Surgical

This substantial funding boost is attributed to the enthusiastic participation of new investors from both the United States and Switzerland. The infusion of capital is strategically earmarked to propel the advancement of LEM Surgical’s product development initiatives and readiness for FDA submission in the second half of 2024. With this latest injection of capital, LEM Surgical is well-positioned to achieve its objectives and to further solidify its potential in the field of surgical robotics.

Yossi Bar, founder and CEO of LEM Surgical, expressed the company’s vision, stating, “Our goal is to revolutionize the experience for surgeons, clinical teams, and hospitals engaged in robotic surgery. We deeply appreciate the trust and support of our new investors. It underscores the unwavering confidence our investors have in the future success of our groundbreaking technology.”

About LEM Surgical AG

LEM Surgical is at the forefront of shaping the future through the creation of the next generation of robotic surgery platforms. The primary focus of its development efforts is centered around surpassing the capabilities of existing robotic platforms for spine surgery.

The company was founded in 2021 by Prof. Dr. Stefan Weber (CEO, CAScination AG), Marco Matulic (CTO, CAScination AG), Simon Michel (CEO, Ypsomed Group), Prof. Dr. Andreas Raabe (Director, Department of Neurosurgery, Inselspital Bern) and Yossi Bar (previously Director R&D at Mazor Robotics Ltd).

Follow on LinkedIn www.linkedin.com/company/lem-surgical-ag/

www.lemsurgical.com

Contact Information

Yossi Bar
Chief Executive Officer
communications@lemsurgical.com

SOURCE: LEM Surgical AG

View the original press release on newswire.com.

Staff

Recent Posts

Endogenex Highlights 48-Week REGENT-1 Clinical Study Results at Digestive Disease Week 2025

Novel Endoscopic Procedure Demonstrates Substantial and Durable Reduction in Insulin Resistance and Improvement in Beta…

2 hours ago

SlimJaro Canada, Australia, UK, Reviews, Official Website, Discount Code, Trustpilot Complaints

Slimjaro Slimjaro Lakeland, FL, May 03, 2025 (GLOBE NEWSWIRE) -- SlimJaro Canada: The Revolutionary Fat-Burning…

2 hours ago

Javy Protein Coffee Under Review: Best Protein Coffee with Premium Ingredients by Javy Protein Coffee

Discover why Javy Protein Coffee is the best protein coffee for energy, recovery, and flavor.…

2 hours ago

Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08

PURCHASE, N.Y., May 02, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader…

2 hours ago

INP and Fight For Life Club Foundation Make History: Two Pediatric Living Donor Liver Transplants in One Week

Dallas, Texas, May 02, 2025 (GLOBE NEWSWIRE) -- In a historic medical achievement, the National…

2 hours ago

RaySearch Laboratories and Vision RT present innovations in surface guided treatment planning at ESTRO

STOCKHOLM, May 3, 2025 /PRNewswire/ -- At this week's ESTRO conference in Vienna, RaySearch Laboratories…

5 hours ago